Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3820 - Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Hsiang-Fong Kao

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

H. Kao1, R. Hong2

Author affiliations

  • 1 Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 2 Department Of Oncology, National Taiwan University Hospital, Taipei/TW

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3820

Background

Head and neck squamous cell carcinoma (HNSCC) is an important malignancy in Taiwan. Anti-PD-1, including nivolumab or pembrolizumab (pembro), had shown the efficacies against recurrent or metastatic (R/M) HNSCC. Afatinib, an irreversible EGFR tyrosine kinase inhibitor (TKI), had showed its activity against head and neck squamous cell carcinoma. In vitro and animal study showed that afatinib can inhibit macrophage function, increase antigen presentation, and augment the T cell response. The role of afatinib for cancer immunotherapy have not been explored in human. We hypothesized that adding afatinib with pembro may improve the treatment efficacy for patients with R/M HNSCC.

Methods

For HNSCC patients who decided to take pembro, the combination with afatinib would be discussed between the physician and the patient. Pembro was planned for 4 cycles. Afatinib was prescribed concurrently with pembro, and will be kept after discontinuation of pembro, until disease progression. For patients taking pembrolizumab and afatinib (P+A), the medical records were reviewed. Patients who have monotherapy with pembrolizumab or afatinib before the P+A were excluded. RECIST 1.1 were used for evaluating tumor response.

Results

From Nov. 1, 2016 to Sep. 30, 2017, 41 R/M HNSCC patients (pts) took P+A. The median age was 59 years, and 38 pts were men. The cancer types were: oral cavity: 29 pts, oropharynx: 5 pts, and hypopharynx: 7 pts. The initial treatments were: pembrolizumab 200mg: 27pts; 2mg/kg: 14pts. Eighteen pts are platinum naïve, and 23 pts are platinum refractory. Until Mar. 30, 2018, the median follow-up was 7.6 months. The clinical response was: CR+PR 24/41 (58.5%, 95% CI: 42.8% -74.3%), SD: 9/41, PD: 8/41. The median PFS was 7.2 (5.0-9.3) months. The median of OS was not reached. The most common toxicities were: diarrhea 56%, skin rash 44%, mucositis 32%, and hand-foot-skin reaction 24%. The incidence of grade 3 or 4 toxicities was 3/41. No pneumonitis were noted in the cohort.

Conclusions

The addition of afatinib with pembrolizumab showed good efficacies and tolerable toxicities. Biomarker studies are ongoing. Further confirmatory prospective trial is indicated.

Clinical trial identification

Legal entity responsible for the study

Hsiang-Fong Kao.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.